loading
Adverum Biotechnologies Inc stock is traded at $2.70, with a volume of 61,989. It is up +1.12% in the last 24 hours and up +4.65% over the past month. Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
See More
Previous Close:
$2.67
Open:
$2.69
24h Volume:
61,989
Relative Volume:
0.17
Market Cap:
$56.40M
Revenue:
-
Net Income/Loss:
$-94.11M
P/E Ratio:
-0.4493
EPS:
-6.01
Net Cash Flow:
$-86.06M
1W Performance:
-2.53%
1M Performance:
+4.65%
6M Performance:
-39.87%
1Y Performance:
-66.63%
1-Day Range:
Value
$2.605
$2.75
1-Week Range:
Value
$2.605
$2.89
52-Week Range:
Value
$1.78
$8.58

Adverum Biotechnologies Inc Stock (ADVM) Company Profile

Name
Name
Adverum Biotechnologies Inc
Name
Phone
(650) 649-1004
Name
Address
100 CARDINAL WAY, REDWOOD CITY, CA
Name
Employee
155
Name
Twitter
@adverumbio
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
ADVM's Discussions on Twitter

Compare ADVM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ADVM
Adverum Biotechnologies Inc
2.70 55.78M 0 -94.11M -86.06M -6.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-25-24 Initiated Oppenheimer Outperform
Apr-30-24 Initiated H.C. Wainwright Buy
Jul-07-22 Upgrade Truist Hold → Buy
Jul-23-21 Downgrade Cantor Fitzgerald Overweight → Neutral
May-03-21 Downgrade SVB Leerink Outperform → Mkt Perform
Apr-29-21 Downgrade Chardan Capital Markets Buy → Neutral
Apr-29-21 Downgrade RBC Capital Mkts Outperform → Sector Perform
Apr-29-21 Downgrade Truist Buy → Hold
Dec-16-20 Initiated UBS Neutral
Nov-12-20 Upgrade Raymond James Underperform → Mkt Perform
Jun-26-20 Downgrade Raymond James Mkt Perform → Underperform
May-13-20 Initiated RBC Capital Mkts Outperform
May-05-20 Upgrade SunTrust Hold → Buy
Apr-28-20 Initiated Goldman Buy
Mar-16-20 Initiated SVB Leerink Outperform
Feb-10-20 Upgrade Cantor Fitzgerald Neutral → Overweight
Feb-10-20 Upgrade Chardan Capital Markets Neutral → Buy
Oct-15-19 Reiterated Chardan Capital Markets Neutral
Sep-13-19 Reiterated Chardan Capital Markets Neutral
Jun-14-19 Resumed Raymond James Mkt Perform
Nov-02-18 Downgrade Raymond James Outperform → Mkt Perform
Nov-02-18 Downgrade SunTrust Buy → Hold
Sep-21-18 Initiated Cantor Fitzgerald Overweight
Aug-30-18 Initiated SunTrust Buy
Feb-15-18 Resumed Piper Jaffray Overweight
Oct-12-17 Initiated Raymond James Outperform
View All

Adverum Biotechnologies Inc Stock (ADVM) Latest News

pulisher
Jul 25, 2025

Is Adverum Biotechnologies Inc. stock a growth or value playBreakout portfolio performance - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Adverum Biotechnologies Inc. Stock Analysis and ForecastUnrivaled growth potential - Autocar Professional

Jul 25, 2025
pulisher
Jul 23, 2025

What analysts say about Adverum Biotechnologies Inc. stockTurbocharged investment results - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is Adverum Biotechnologies Inc. a good long term investmentHigh-octane financial growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Adverum Biotechnologies Inc. stock priceOutstanding stock performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 16, 2025

Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream - GlobeNewswire Inc.

Jul 16, 2025
pulisher
Jul 16, 2025

How Adverum Biotechnologies Inc. stock performs during market volatilityFree Access to Investment Community - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

what makes adverum biotechnologies inc. stock price move sharplyDaily Volume Leaders - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Adverum Biotechnologies Inc. stock price move sharplyFree Access to Community - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Adverum Biotechnologies Inc. stock attracts strong analyst attentionProven High Yield Signals - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Adverum Biotechnologies Up 22%, Insiders Still Down After US$526.8k Purchase - simplywall.st

Jul 15, 2025
pulisher
Jul 15, 2025

Reversal Of Fortune For Adverum Biotechnologies Insiders Who Made A US$526.8k Purchase - Yahoo Finance

Jul 15, 2025
pulisher
Jun 30, 2025

Adverum Biotechnologies, Inc.(NasdaqCM: ADVM) dropped from Russell 3000 Index - MarketScreener

Jun 30, 2025
pulisher
Jun 18, 2025

Adverum Biotechnologies shareholders approve stock option repricing - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Adverum Biotechnologies shareholders approve stock option repricing By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 13, 2025

Adverum Biotechnologies’ SWOT analysis: gene therapy stock faces pivotal year - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 06, 2025

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

Adverum Biotechnologies (NASDAQ:ADVM) versus Metagenomi (NASDAQ:MGX) Head-To-Head Analysis - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Adverum Awards 14,610 Shares in Stock Options and RSUs to Key New Hires - Stock Titan

Jun 05, 2025
pulisher
May 16, 2025

Adverum Biotechnologies Reports Q1 2025 Financial Results - TipRanks

May 16, 2025
pulisher
May 15, 2025

Adverum Biotechnologies (ADVM) Sees Price Target Adjustment by RBC Capital | ADVM Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Adverum Biotechnologies (ADVM) Receives Continued Buy Rating from Chardan Capital | ADVM Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Adverum Biotechnologies (ADVM) Price Target Reduced by RBC Capit - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Adverum Biotechnologies (ADVM) Rating Reiterated at 'Buy' by HC Wainwright | ADVM Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

RBC Cuts Price Target on Adverum Biotechnologies to $4 From $5, Keeps Sector Perform, Speculative Risk - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Adverum Biotechnologies: Q1 Earnings Snapshot - CT Insider

May 15, 2025

Adverum Biotechnologies Inc Stock (ADVM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Adverum Biotechnologies Inc Stock (ADVM) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Seyedkazemi Setareh
CHIEF DEVELOPMENT OFFICER
May 15 '25
Sale
2.00
924
1,848
13,768
Fischer Laurent
CEO, PRESIDENT AND DIRECTOR
May 15 '25
Sale
2.00
9,126
18,252
87,488
Leonard Braden Michael
10% Owner
Mar 26 '25
Buy
5.04
20,407
102,841
125,207
Leonard Braden Michael
10% Owner
Mar 27 '25
Buy
5.19
16,593
86,089
141,800
Leonard Braden Michael
10% Owner
Apr 22 '25
Buy
3.00
300,000
900,000
3,057,526
Leonard Braden Michael
10% Owner
Apr 23 '25
Buy
2.98
50,000
148,950
191,800
Leonard Braden Michael
10% Owner
Mar 31 '25
Buy
4.38
19,566
85,668
2,742,317
Leonard Braden Michael
10% Owner
Apr 02 '25
Buy
4.04
15,209
61,408
2,757,526
Leonard Braden Michael
10% Owner
Mar 26 '25
Buy
5.04
20,407
102,841
125,207
Leonard Braden Michael
10% Owner
Mar 18 '25
Buy
4.69
62,341
292,418
2,667,161
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):